BioPharmX, Inc.
Records under this name other than patents BioPharmX, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,474,720 | Dosage form comprising an active ingredient and a plurality of solid porous microcarriers Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,391,108 | Pharmaceutical tetracycline composition for dermatological use Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,881,672 | Pharmaceutical tetracycline composition for dermatological use Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,933,018 | Isotretinoin formulations and uses and methods thereof Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,471,408 | Isotretinoin formulations and uses and methods thereof Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,918,998 | Pharmaceutical tetracycline composition for dermatological use Formerly held Lapsed on the fee record Ended Mar 20, 2026 · USPTO record | Lapsed on the fee record | Ended Mar 20, 2026 | USPTO record |
| US 9,901,586 | Dosage form comprising an active ingredient and a plurality of solid porous microcarriers Formerly held Lapsed on the fee record Ended Feb 27, 2026 · USPTO record | Lapsed on the fee record | Ended Feb 27, 2026 | USPTO record |
| US 10,391,121 | Magnesium chloride composition for dermatological use Formerly held Lapsed on the fee record Ended Aug 27, 2023 · USPTO record | Lapsed on the fee record | Ended Aug 27, 2023 | USPTO record |
| US 10,159,686 | Dosage form comprising an active ingredient and a plurality of solid porous microcarriers Formerly held Lapsed on the fee record Ended Dec 25, 2022 · USPTO record | Lapsed on the fee record | Ended Dec 25, 2022 | USPTO record |
| US 10,034,899 | Solid oral dosage form for breast symptoms Lapsed on the fee record Ended Jul 31, 2022 · USPTO record | Lapsed on the fee record | Ended Jul 31, 2022 | USPTO record |